NPS Reports Two Teduglutide Abstracts Accepted for Presentation at American College of Gastroenterology Annual Scientific Meetin

The details of the two poster presentations, which will be presented on
October 25, 2009 from 3:30 -- 7:00 PM PT, are summarized below.

Abstract P272: "Teduglutide (TG), a Dipeptidyl-peptidase IV
Resistant Glucagon-like Peptide 2 (GLP-2) Analogue, Improves Lean
Body Mass and Total Mineral Content in Short Bowel Syndrome (SBS)
Patients Depending on Home Parenteral Nutrition (PN). Dual Energy
X-ray Absorptiometry (DEXA) Results from a Randomized,
Placebo-controlled, 24-week Study" by P. Jeppesen et al.
Abstract P273: "Teduglutide (TG) Improves Electrolyte and
Wet Weight Absorption in Short Bowel Syndrome Patients, but this
is not correlated to increases in Plasma Citrulline (PC)" by P.
Jeppesen et al.

The ACG 2009 program and abstracts are available online and can be
accessed at http://www.acg.gi.org/acgmeetings/
by clicking on the schedule page and searching abstracts for teduglutide.

About Short Bowel Syndrome (SBS)

SBS is a highly disabling condition that impairs quality of life and can
lead to serious life-threatening complications. SBS typically arises
after extensive resection of the bowel. There are an estimated 10,000 to
15,000 SBS patients in North America who are dependent on parenteral
nutrition (PN), the cost of which can exceed $100,000 annually per
patient. SBS patients suffer from malnutrition, severe diarrhea,
dehydration, fatigue, osteopenia, and weight loss due to an inability to
absorb adequate amounts of nutrients, fluid, and electrolytes. The goals
of current treatment are to maintain fluid, electrolytes and nutrient
balances through dietary management, including the use of PN. Long-term
complications of the condition may include an increased risk of systemic
infections due to the presence of an intravenous feeding line,
degenerative changes in the bones and nerves due to vitamin and mineral
deficiencies, and liver failure. Potential benefits derived from reduced
dependence on PN may include improved nutrition and hydration, lower
rates of infections, and improved quality-of-life due to more time away
from PN, which may provide greater mobility and improved sleep.

About GATTEX(TM) (teduglutide)

GATTEX (teduglutide) is a proprietary analog of human glucagon-like
peptide 2 that stimulates the repair and regeneration of cells lining
the intestine. GATTEX is in Phase 3 clinical development to reduce
dependence on parenteral nutrition (PN) in patients with short bowel
syndrome (SBS). NPS has reported positive findings from completed
studies in which GATTEX demonstrated a favorable safety profile and
significant reductions in mean PN volume from pretreatment baseline were
observed. NPS is also advancing preclinical studies to evaluate
teduglutide in additional intestinal failure related conditions.

NPS has granted Nycomed the rights to develop and commercialize
teduglutide outside of North America and the two companies are
collaborating on the development of teduglutide for the treatment of
gastrointestinal disorders.

Teduglutide has received orphan drug designation for the treatment of
SBS from the U.S. Food and Drug Administration and the European
Medicines Agency.

About NPS Pharmaceuticals

NPS Pharmaceuticals is developing new treatment options for patients
with rare gastrointestinal and endocrine disorders. The company is
currently conducting two Phase 3 registration studies. Teduglutide, a
proprietary analog of GLP-2, is being evaluated as GATTEX(TM) in a Phase 3
registration study known as STEPS for intestinal failure associated with
short bowel syndrome and in preclinical development for gastrointestinal
mucositis and other pediatric indications. NPSP558 (parathyroid hormone
1-84 [rDNA origin] injection) is being evaluated in a Phase 3
registration study known as REPLACE as a hormone replacement therapy for
hypoparathyroidism. NPS complements its proprietary programs with a
royalty-based portfolio of products and product candidates that includes
agreements with Amgen, GlaxoSmithKline, Kyowa Kirin, Nycomed, and
Ortho-McNeil. Additional information is available at http://www.npsp.com.

"NPS" and "NPS Pharmaceuticals" are the company's registered trademarks.

Statements made in this press release, which are not historical in
nature, constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of 1995.
These statements are based on the company's current expectations and
beliefs and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in
the forward-looking statements. Risks associated to the company's
business include, but are not limited to, the risks associated with any
failure by the company to successfully complete its preclinical and
clinical studies within the projected time frames or not at all, the
risk of not gaining marketing approvals for GATTEX and NPSP558, the
risks associated with the company's strategy, the risks associated with
the company's auction-rate securities, as well as other risk factors
described in the company's periodic filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K and Form
10-Qs. All information in this press release is as of the date of this
release and NPS undertakes no duty to update this information.

SOURCE: NPS Pharmaceuticals, Inc.

Investors: 
NPS Pharmaceuticals, Inc. 
Susan M. Mesco, 908-450-5516 
smesco@npsp.com 
or 
Media: 
Lazar Partners Ltd. 
Hollister Hovey, 212-867-1762 
hhovey@lazarpartners.com

For full details on Nps Pharmaceuticals Inc (NPSP) NPSP. Nps Pharmaceuticals Inc (NPSP) has Short Term PowerRatings at TradingMarkets. Details on Nps Pharmaceuticals Inc (NPSP) Short Term PowerRatings is available at This Link.